Remote Ischemic Conditioning  by Heusch, Gerd et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 2 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 1 0 . 0 3 1THE PRESENT AND FUTURE
STATE-OF-THE-ART REVIEWRemote Ischemic Conditioning
Gerd Heusch, MD,* Hans Erik Bøtker, MD, PHD,y Karin Przyklenk, PHD,z Andrew Redington, MD,x
Derek Yellon, PHD, DSCkABSTRACTFro
Es
Ins
To
He
rec
Re
the
of
fro
Lo
He
for
Sh
Lis
Yo
MaIn remote ischemic conditioning (RIC), brief, reversible episodes of ischemia with reperfusion in one vascular bed, tissue,
or organ confer a global protective phenotype and render remote tissues and organs resistant to ischemia/reperfusion
injury. The peripheral stimulus can be chemical, mechanical, or electrical and involves activation of peripheral sensory
nerves. The signal transfer to the heart or other organs is through neuronal and humoral communications. Protection can
be transferred, even across species, with plasma-derived dialysate and involves nitric oxide, stromal derived factor-1a,
microribonucleic acid-144, but also other, not yet identiﬁed factors. Intracardiac signal transduction involves: adenosine,
bradykinin, cytokines, and chemokines, which activate speciﬁc receptors; intracellular kinases; and mitochondrial func-
tion. RIC by repeated brief inﬂation/deﬂation of a blood pressure cuff protects against endothelial dysfunction and
myocardial injury in percutaneous coronary interventions, coronary artery bypass grafting, and reperfused acute
myocardial infarction. RIC is safe and effective, noninvasive, easily feasible, and inexpensive. (J Am Coll Cardiol
2015;65:177–95) © 2015 by the American College of Cardiology Foundation.R emote ischemic conditioning (RIC) is theintriguing phenomenon whereby brief, re-versible episodes of ischemia and reperfu-
sion applied in one vascular bed, tissue, or organ
confer global protection, rendering remote tissues
and organs resistant to ischemia/reperfusion injury.
Its discovery 2 decades ago in the heart (1) was
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ABBR EV I A T I ON S
AND ACRONYMS
AMI = acute myocardial
infarction
CABG = coronary artery
bypass grafting
CMR = cardiac magnetic
resonance
PCI = percutaneous coronary
intervention
RIC = remote ischemic
conditioning
RIPC = remote ischemic
pre-conditioning
RISK = reperfusion injury
salvage kinase
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
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178HISTORICAL BACKGROUND
AND CONCEPT OF RIC
EVOLUTION OF THE PARADIGM. Although
this ﬁrst report of “intracardiac” RIC was
provocative and met with considerable skep-
ticism (4), the concept also engendered cu-
riosity and raised the question: can the RIC
paradigm be extrapolated to other remote
triggers?
Spat ia l evolut ion : f rom intracard iac to
interorgan RIC . During the past 2 decades,
multiple variations on the theme of RIC
have been investigated, encompassing both
in vitro and in vivo models. Cardioprotection
by collection and transfer of perfusate among
isolated buffer-perfused hearts is a notable
example (5–8). Speciﬁcally, coronary efﬂuent
released from donor rabbit hearts throughouta standard, conventional pre-conditioning stimulus
(3 cycles of 5-min global ischemia with 10-min
reperfusion) or a time-matched control period was
collected, reoxygenated, warmed, and used as the
perfusate for 2 cohorts of naïve, acceptor hearts. All
4 groups of hearts then underwent 40 min of sus-
tained global ischemia. Infarct sizes were signiﬁ-
cantly smaller in both, donor hearts subjected to brief
pre-conditioning ischemia and naïve acceptor hearts
that received the efﬂuent from pre-conditioned do-
nors, versus donor and acceptor control subjects.
There was no difference in the magnitude of the
infarct-sparing effect seen in donor– and acceptor–
pre-conditioned groups, implying that the efﬁcacy
of cardioprotection triggered by RIC was comparable
to that achieved by conventional ischemic pre-
conditioning (5). This general strategy, involving
transfer of efﬂuent or perfusate, has been reﬁned
to include collection of serum following brief pre-
conditioning ischemia applied in vivo and its ad-
ministration to either isolated hearts or cultured cells
subjected to a sustained ischemic or hypoxic insult
(9–11). This strategy also provided evidence of cross-
species protection by RIC, including treatment of
isolated buffer-perfused rabbit hearts with human
serum (9,11).
It could be argued that intracardiac RIC or
cardioprotection achieved by transfer of perfusate
between hearts is a laboratory curiosity providing
mechanistic insight, but of limited translational re-
levance. Accordingly, the observation of interorgan
RIC was a pivotal pre-clinical advance (12). Initial
evidence revealed that brief episodes of ischemia/
reperfusion in kidney and mesentery rendered the
heart resistant to infarction (12–15). Moreover, anumber of studies documented RIC-induced atten-
uation of ischemia/reperfusion injury in brain,
lungs, liver, kidney, intestine, skin, and other tissues
(reviewed in Candilio et al. [16]). However, the ﬁrst
reported seminal extension of interorgan RIC in a
clinically-relevant, large-animal (swine) model (17),
which demonstrated that brief episodes of periph-
eral limb ischemia, achieved by simple tourniquet
occlusion of one hindlimb, was sufﬁcient to evoke a
profound reduction in myocardial infarct size,
accelerated subsequent implementation of phase II
trials aimed at establishing efﬁcacy in patients (17).
Conceptua l evolut ion : f rom ischemic to non-
i schemic t r iggers . In the aforementioned studies,
intercardiac and interorgan RIC were (by deﬁnition)
initiated by a brief ischemic stimulus. However, ac-
cumulating evidence from a spectrum of in vivo and
in vitro models (some involving perfusate transfer
among models) suggests that transient ischemia or
interruption of blood ﬂow is not a requisite trigger
for remote protection. Multiple alternative triggers
capable of recapitulating the infarct-sparing effect
of RIC have been proposed, including peripheral
nociception (initiated by skin incisions made on the
abdomen and termed “remote pre-conditioning of
trauma”), direct peripheral nerve stimulation, and
noninvasive transcutaneous nerve stimulation and
electroacupuncture (18–23). Perhaps the most attrac-
tive, for its potential as a clinical cardioprotective
strategy, is nontraumatic peripheral nociception
instigated by chemical stimulation of sensory C-ﬁbers
in the skin (18,21). A >70% reduction in infarct size
was reported in mice treated with 0.1% capsaicin
cream, applied topically to a 2 cm2 area of skin along
the abdominal midline 15 min before the onset of
coronary artery occlusion, compared with untreated
control subjects (18). In spite of its inherent appeal,
this concept has not yet been translated to clinical
investigation.
Tempora l var iants : remote pre- , per - , and post-
cond i t ion ing . In all studies discussed thus far, the
remote conditioning stimulus was administered pro-
phylactically in the w30- to 40-min period before the
onset of sustained myocardial ischemia. However,
pre-treatment is not a requirement for RIC-induced
cardioprotection: reduction of infarct size has also
been described with concurrent application of the
remote ischemic stimulus during sustained coro-
nary occlusion (remote ischemic per-conditioning)
or at the time of reperfusion (remote ischemic post-
conditioning) (24,25).
The ﬁrst documentation of infarct size reduction
with remote per-conditioning utilized brief renal
ischemia/reperfusion as the trigger, applied during
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179the ﬁnal minutes of coronary artery occlusion (26).
This approach provided proof-of-principle, but has
obvious practical limitations as therapy. However,
evidence from the swine model demonstrated a
signiﬁcant infarct-sparing effect of 4 5-min cycles of
intermittent limb ischemia administered during a
40-min period of left anterior descending coronary
occlusion (27), providing the rationale for the land-
mark clinical trial in which limb ischemia was
applied during transport of patients with suspected
acute myocardial infarction (AMI) to the hospital
(28). Cardioprotection with remote ischemic post-
conditioning was ﬁrst demonstrated in swine (29)
and subsequently corroborated in other models, in-
cluding rabbit and rat (8,30). In each case, the pro-
tective stimulus was initiated immediately upon
relief of the sustained myocardial ischemia.
THE PRE-CLINICAL CONSENSUS. A general consensus
regarding RIC has emerged: with rare exceptions (31),
there is consistent evidence among diverse models
and species that brief ischemia/reperfusion applied
in a remote tissue or organ confers cytoprotection
against ischemia/reperfusion injury. When the heart
is the target organ, the gold standard of RIC-induced
protection is reduction of myocardial infarct size.
However, remote ischemic pre-conditioning (RIPC)
protects the myocardium, but also other parenchymal
organs (16) and, notably, the vasculature. Endothelial
dysfunction from ischemia/reperfusion can serve as
a surrogate for studies on cardioprotection by RIC
in healthy humans, but it is unclear whether extrap-
olation from preservation of peripheral vasomotion
to cardioprotection is also true mechanistically (32).
Among the multiple variants of RIC, is any option
superior for evoking cardioprotection? Interorgan
(rather than intracardiac) conditioning, achieved via
intermittent limb ischemia or, potentially, via non-
traumatic peripheral nociception, is among the more
appealing and practical strategies. Studies where
peripheral limb ischemia is the RIC stimulus have
mostly employed 3 or 4 episodes of 5-min arm and/or
leg ischemia interspersed with 5-min reperfusion
periods. However, these are empiric choices, the
optimal algorithm has not been identiﬁed, and it
has been postulated that “hyperconditioning” (i.e., an
as-yet undeﬁned, excessive number of conditioning
episodes) may be deleterious (33,34). With regard
to timing, outcomes of the limited number of head-
to-head comparisons revealed no apparent differ-
ence in efﬁcacy of RIPC, remote pre-conditioning, and
post-conditioning (35,36). The paradigms of remote
ischemic per-conditioning and post-conditioning may
be particularly relevant, as they expand the potential
scope for clinical translation of RIC.SIGNAL TRANSDUCTION OF RIC
NEURONAL SIGNAL TRANSFER FROM THE REMOTE
ORGAN TO THE HEART. Signal transduction to the
heart from the remote organ where the RIC protocol
initiates protection appears to involve the somato-
sensory system, the spinal cord, and the autonomous
nervous system (Central Illustration). The stimulus
can originate not only from local ischemia/reperfu-
sion injury in an organ other than the heart (e.g.,
mesentery [12,14,37] or limb [35,38–42]), but also from
local surgical trauma (18–20,41); local activation of
sensory ﬁbers by capsaicin (18,21,35), bradykinin
(14,20), or adenosine (39); and local electrical nerve
stimulation (21,23). Accordingly, local anesthesia with
lidocaine (18) or a sensory nerve blocker (21) and
transection of the peripheral nerve (21,35,39,40)
abrogated protection by RIPC, although femoral
nerve transection did not abrogate protection by limb
RIPC in mice in one study (42).
The local release mechanism in response to a
nociceptive stimulus involves protein kinase Cg in
rats (20) and is inhibited by a nitric oxide donor
(39). Whereas the causal involvement of peripheral
nociceptive sensory nerves is unequivocal, the nature
and transfer to the heart of the released transmitter
molecule through neuronal or humoral pathways
remains ambiguous. A blood-derived dialysate was
able to transfer protection to a recipient bioassay
heart after local peripheral adenosine or capsaicin
administration, peripheral nerve stimulation, or
RIPC (21,39), supporting the notion of humoral
transfer of a neuronally-released signal molecule.
This is also suggested by studies in humans, where
the dialysate from diabetic subjects after RIC pro-
vided protection only in the absence of diabetic
neuropathy (11).
Abrogation of protection by RIPC with spinal cord
transection at T7-T10 (18,40) or intrathecal spinal
opioid receptor blockade with naloxone (41) and
infarct size reduction by spinal cord stimulation by
C8-T2 (43) favor a spinal reﬂex response. The efferent
pathway appears to involve the autonomous nervous
system. The ganglionic blocker, hexamethonium,
abrogated protection by local bradykinin administra-
tion or RIPC in most (12,14,18), but not all (38) studies.
Another ganglionic blocker, trimetaphan, also abro-
gated RIPC’s protection from ischemia/reperfusion-
induced endothelial dysfunction in humans (44).
Cardiac sympathetic nerves are involved in attenua-
tion of the observed infarct size reduction upon spi-
nal cord stimulation, and this effect is attenuated
by the a1-blocker, prazosin, and the ß-blocker, timolol
(43). Another ß-blocker, propranolol, also abrogated
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gotomy (35,40) or atropine (40,45) abrogated the
protection by limb pre-conditioning (35,40).
In conclusion, local injury during remote organ
pre-conditioning activates nociceptive ﬁbers, which
release an unidentiﬁed molecule into the blood and/
or signal through the spinal cord to activate both
cardiac vagal and sympathetic efferents to release
cardioprotective substances. Most of the previously
discussed data originate from rodent models of RIC
or from studies with transfer of dialysate to rodent
hearts. However, neuronal involvement in protection
by RIPC in humans undergoing coronary artery
bypass grafting (CABG) or aortic valve surgery issuggested by its abrogation with propofol, but not
isoﬂurane anesthesia (46–48).
HUMORAL SIGNAL TRANSFER FROM THE REMOTE
ORGAN TO THE HEART. In early studies of local
pre-conditioning, coronary efﬂuent from a pre-
conditioned heart induced cardioprotection in a
naïve acceptor heart (5). The presence of a circulating
cardioprotective factor after RIPC was ﬁrst demon-
strated in a porcine transplant model (49), where
RIPC of the limb in an acceptor pig provided potent
cardioprotection to the subsequently transplanted
and denervated donor heart. Subsequent studies
conﬁrmed the presence of a circulating element and
further characterized the nature of the factor(s). In an
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181isolated rabbit heart model (9), plasma from remotely
pre-conditioned animals was cardioprotective when
perfused into an isolated naïve heart. The plasma
dialysate using a 15-kDa membrane was similarly
cardioprotective. When processed over a C18 column,
the small hydrophobic molecule eluate provided
potent cardioprotection, along with a protective
kinase signature. Importantly, when the dialy-
sate was given to isolated fresh cardiomyocytes
(excluding neuronal inﬂuence), the resistance of
cardiomyocytes to simulated ischemia/reperfusion
injury mimicked that of a local pre-conditioning
stimulus. Subsequent animal studies using such
Langendorff bioassays conﬁrmed that RIC induced
by femoral nerve stimulation, transcutaneous pe-
ripheral nerve stimulation, capsaicin, and even
electroacupuncture appear to work, at least in part,
via release of cardioprotective factors into the blood
(21–23,39).
Langendorff bioassays have also been used to test
for the presence of circulating cardioprotective fac-
tors in human RIC. Depending on whether peripheral
neuropathy was present, dialyzed plasma from dia-
betic patients subjected to RIC had differential re-
sponses, conﬁrming interaction between the neural
and humoral components of remote conditioning
(11). Whereas plasma from diabetic patients without
neuropathy was highly cardioprotective in naïve
acceptor rabbit hearts, patients with peripheral neu-
ropathy failed to provide cardioprotective plasma.
Most recently, RIPC had no effect on exercise per-
formance in heart failure patients (50). However, in
the isolated mouse heart bioassay, plasma from heart
failure patients was cardioprotective at baseline,
but provided no additional cardioprotection after
RIPC. When the results were stratiﬁed for the degree
of baseline cardioprotection, those with low base-
line cardioprotective activity showed signiﬁcant
improvement in their exercise function after clinical
RIPC, suggesting that some patients lacking a pre-
existing cardioprotective milieu may beneﬁt from
RIPC.
Several recent studies identiﬁed putative contrib-
utors to the humoral response. A recent proteomic
study identiﬁed multiple potential cardioprotective
targets released into the blood after a limb RIC
protocol (51). Several speciﬁc circulating molecules
also were studied in detail: the shear-stress-related
release of nitric oxide, secondary to reactive hyper-
emia induced by transient limb ischemia, is expected
to increase plasma nitrite in the blood, which is
known to be cardioprotective (52). Conversely, RIPC
was inactive in genetically-modiﬁed animals deﬁ-
cient in endothelial nitric oxide synthase (42).Pre-treatment with the nitrite scavenger sulfanil-
amide abrogated the cardioprotective effect of plasma
obtained after limb RIC in human volunteers, when
used to perfuse naïve mouse hearts in a Langendorff
bioassay. The clinical effect of nitrite is less certain.
The NIAMI (Nitrites in Acute Myocardial Infarction)
investigators (53) studied 229 patients with acute
ST-segment elevation myocardial infarction (STEMI)
randomized to receive an infusion of sodium nitrite
or placebo. Nitrite failed to modify either myocar-
dial infarction size or any of the secondary endpoints
(e.g., troponin, creatine kinase, or left ventricular
function), suggesting that the clinical effect of RIC is
beyond that of nitrite alone.
Stromal-derived factor-1a is a small chemokine
that fulﬁlls the criteria for a putative circulating
effector (9), and is cardioprotective via its interac-
tion with its chemokine receptor 4 (54). Circulating
plasma levels of stromal-derived factor-1a in-
creased in rats subjected to RIPC by limb ischemia/
reperfusion, and the cardioprotection of RIPC was
partially abrogated by pre-treatment of the animals
with a speciﬁc inhibitor (55). The lack of complete
abrogation in this model suggests involvement of
other factors.
Finally, a microribonucleic acid (microRNA) was
recently shown to play a role in the pre-conditioning
effect of transient limb ischemia/reperfusion.
MicroRNA-144 levels were increased in mouse
myocardium after RIPC and markedly reduced after
ischemia/reperfusion injury. In subsequent experi-
ments, the effect of RIC was completely abrogated
by the use of a speciﬁc antagomir to microRNA-144.
Conversely, intravenous microRNA-144 was car-
dioprotective, both acutely and 3 days after admin-
istration. Importantly, microRNA-144 levels were
increased in the plasma of mice and humans sub-
jected to limb RIC. Plasma carriage of microRNAs, to
prevent digestion by circulating RNase, has been
demonstrated within lipoprotein complexes in asso-
ciation with speciﬁc carrier proteins, such as argo-
naute, and in exosomes (56–59). Interestingly, the
total number of exosomes in mouse plasma after RIC
did not increase (60), although others observed
increased numbers of exosomes following RIC in both
rats and humans (61). However, the hairpin precursor
of microRNA-144 in the exosome pellet increased
4-fold, and single-stranded microRNA-144 levels
increased substantially in the plasma supernatant
after RIC. Plasma microRNA-144 colocated with
argonaute protein complexes, suggesting that this
may be the plasma carriage mechanism after release
of microRNA-144 precursor from the exosome.
Although the exosome fraction was not tested for
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182cardioprotective activity in that study, efﬂuent from a
pre-conditioned heart was able to protect a second
heart unless microvesicles and exosomes were
removed, demonstrating that protection depends
upon their presence (62). In summary, more work is
required to identify whether microRNA-144, other
microRNAs, chemokines, and perhaps undiscovered
circulating factors may act either alternately or in
concert as the humoral signal transferring protection
to the heart. Nitric oxide, stromal-derived factor-1a,
and microRNA-144 are clearly humoral transfer
signals, but they do not fully explain the RIC
phenomenon.
SIGNAL TRANSDUCTION OF RIC IN THE HEART. The
search for signaling molecules/mechanisms of RIC
has largely focused on signals identiﬁed in local
ischemic pre- and post-conditioning studies (63,64).
Early studies using pharmacological antagonists
identiﬁed the involvement of adenosine (13,26), bra-
dykinin (14,19,65), opioids (37,66,67), epoxyeicosa-
trienoic acids (19), reactive oxygen species (66), and
adenosine triphosphate (ATP)-dependent potassium
channels (13,27), but could not dissect whether these
molecules/mechanisms were involved in signal gen-
eration within the remote organ, transfer of the signal
to the heart, cardioprotective signaling in the heart,
or any combination of these steps. To attribute
signaling to the heart, the signal must be demon-
strated to localize in the myocardium or an antagonist
must be given in the transfer ﬂuid obtained after a
RIC protocol in a donor organism, then administered
to an isolated recipient and target heart. However,
isolated bioassay hearts contain a number of different
cellular compartments in addition to cardiomyocytes
including innervation, vasculature, interstitial cells,
and matrix with resident leukocytes/immune cells.
Also, most signaling molecules/mechanisms have
thus far only been determined in rodent hearts,
and translation to larger mammals or humans cannot
be taken for granted.
With these caveats in mind, there is solid evidence
for a causal involvement of the ligands adenosine
(10,68), bradykinin (18), interleukin-10 (in delayed
RIPC) (69) and stromal-derived factor-1a (55) in the
heart. Adenosine acts on its A1 receptor, which, in
turn, interacts with d and k opioid receptors (68);
bradykinin acts on its B2 receptor (18); and stromal-
derived factor-1a acts on chemokine receptor 4 (55).
Adenosine receptor activation results in improved
mitochondrial function, as evidenced by better
respiration and reduced formation of reactive oxygen
species (10). Bradykinin B2 receptor activation results
in protein kinase Cε activation (18). The action of
interleukin 10 results in increased phosphorylationof protein kinase B (Akt) and endothelial nitric
oxide synthase (69). RIC consistently results in acti-
vation of the reperfusion injury salvage kinase
(RISK) pathway, that is, activation of phosphatidyli-
nositol-4,5-bisphosphate 3-kinase (70), Akt (8,69–72),
extracellular-regulated kinase 1/2 (71), and glycogen
synthase kinase 3ß (73). RISK activation was also
conﬁrmed by abrogation of infarct size reduction
with the respective pharmacological antagonists
(8,70,71) and was not only seen in rodent, but also in
pig hearts (70), in which RISK activation was previ-
ously not found important for protection by ischemic
post-conditioning (74). However, the study with
RISK activation by remote ischemic pre- and per-
conditioning in pigs was confounded by the ambig-
uous ﬁnding that an adenosine antagonist abrogated
RISK activation, rather than protection (70). RIC
also consistently (18,38,43,65) results in activation of
protein kinase C, a key molecule in cardioprotection
(75) with a somewhat ambiguous role (76,77); in
rodent hearts, protein kinase Cε is classically acti-
vated and shifted from the cytosolic to the particu-
late fraction (18,65). The role of hypoxia-inducible
factor (HIF)-1a in RIC is controversial; in 1 study,
infarct size reduction by limb RIPC was abrogated
in heterozygous knockout mice (72), but in another
study, HIF-1a expression was increased by limb RIPC
in wild-type mice, but was not a prerequisite for
protection (73). HIF-1a protein expression is also
increased in right atrial tissue of patients undergoing
cardiac surgery under cardiopulmonary bypass with
RIPC, but its causal involvement in the observed
attenuation of troponin T release remains unclear
(78). Late RIPC in rats increased heme oxygenase-1
protein expression, and its inhibition by zinc proto-
porphyrin abrogated protection (79). As in local
ischemic pre-conditioning (80), limb RIPC in rats
not only reduced infarct size, but also preserved
connexin-43 phosphorylation and localization at
intercalated disks (81); the role of mitochondrial
connexin-43 in RIC has not been addressed.
An unbiased (mass spectrometry) proteomic search
for phosphorylated proteins revealed that limb RIC
increased expression of several phosphoproteins re-
lated to the sarcomeric Z-disc (82). A comprehensive
immunoblotting approach for established cardio-
protective proteins in right ventricular tissue of chil-
dren undergoing repair of Fallot’s tetralogy revealed
no differences in their phosphorylated forms with-
out or with RIPC (83). In left ventricular biopsies
from adult patients undergoing CABG, tyrosine-
phosphorylated signal transducer and activator of
transcription 5 was the only protein among more
than 30 established cardioprotective proteins that
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183was increased by RIPC (84). Autophagy appears to
have no role in human RIPC (85).
Mitochondria are clearly involved in car-
dioprotection by RIC. Human plasma from healthy
volunteers undergoing an RIC protocol had increased
nitrite concentration and increased the concentration
of myocardial nitrite when transferred to an isolated
mouse bioassay heart. Myocardial nitrite was con-
verted to bioactive nitric oxide by myoglobin and
reduced infarct size. In parallel mouse experiments,
the same nitrite-nitric oxide pathway was activated
by RIPC, induced S-nitrosation of mitochondrial pro-
teins, and reduced complex I respiration and reac-
tive oxygen species formation (42). In rabbits with
limb RIPC, blockade of the mitochondrial aldehyde
dehydrogenase-2 by cyanamide abrogated protec-
tion; in parallel experiments in humans with a func-
tionally inactive enzyme polymorphism, endothelial
protection by RIPC was eliminated, supporting the
concept that mitochondrial function is essential in
RIC (86). Better preservation of mitochondrial respi-
ration was also seen in right atrial tissue of patients
undergoing CABG with RIPC, who also had lower
incidence of post-operative atrial ﬁbrillation (87).
Apart from mitochondrial function, RIPC increases
myocardial glycolytic ﬂux in adult, but not in
neonatal rabbit hearts along with reduced infarct size
in adult, but not in neonatal hearts (88). In isolated
hearts from rats that underwent a RIPC protocol,
myocardial microRNA-1, microRNA-2, heat shock
protein-70, and programmed cell death protein
expression were decreased (89). In right atrial tissue
of patients undergoing CABG with RIPC, microRNA-
388-3p expression was increased (87). The biological
meaning of these changes in microRNA expression is
unclear.
Apparently, the intracardiac signal transduction of
RIC largely resembles that of local ischemic pre- and
post-conditioning, with signiﬁcant involvement of
nitric oxide, protein kinase C, the RISK pathway, and
mitochondrial function. The data on myocardial
signal transduction of RIC have not yet been inte-
grated into a more complex and comprehensive
scheme. Surprisingly, the role in RIC of the survival
activating factor enhancement pathway, including
signal transducer and activator of transcription 3, has
not been addressed.
CLINICAL EVIDENCE FOR RIC
EFFECTS OF RIC ON THE HEART: ELECTIVE
ISCHEMIA/REPERFUSION. Patients undergoing elec-
tive CABG and percutaneous coronary intervention
(PCI) change as the demographics of the generalpopulation alter. The percentage of patients age $75
years at the time of operation increased from 17% in
1999 to 29% in 2005 (90). Operated patients had
more comorbidities, with increased rates of hyper-
tension (from 43.7% in 1999 to 68.9% in 2007) and
obesity (from 13% to 17.5% in the same period) and
worse functional and cardiac status (reduced ejection
fraction, hemodynamic instability, and shock) (90).
Improvement in anesthetics and surgical and peri-
operative treatments allows surgeons to accept
patients for operation who, only a few years ago,
would have been refused. Left ventricular ejection
fraction <30% remains the most important deter-
minant of outcome after isolated CABG (91). In
elective CABG and PCI, adverse intermediate and
long-term outcomes relate to periprocedural myo-
cardial injury, including reduction of left ventricular
ejection fraction; hence, the importance of car-
dioprotection beyond cardioplegia and off-pump
surgery. Pre-conditioning by intermittent cross-
clamping of the ascending aorta is invasive and has
recently been comprehensively reviewed (64,92).
The ﬁrst (very small) clinical study evaluating the
effect of RIPC on creatine kinase-myocardial band
release in CABG patients was negative (93). Trans-
lation of RIPC’s protective potential to forearm
endothelium-dependent vasomotion (17) initiated
exploration of the cardioprotective potential of this
approach using biomarkers as an endpoint in cardiac
surgery, such as pediatric cardiac surgery, CABG, and
combined CABG and valvular surgery. Most studies,
including one small pilot study of high-risk patients
(93–102), demonstrated cardioprotective potential
(46,84,87,103–116) (Table 1), with similar ﬁndings
for elective PCI (117–125) (Table 2). Many studies
only included a few patients. Type 2 error might
explain the discrepant results and confounding fac-
tors, including age, comedication, anesthesia, co-
morbidity, and risk factors, may also have inﬂuenced
the efﬁcacy of RIC (126). Concomitant therapy with
beta-blockers (127,128) and statins (129) is cardio-
protective, as is an anesthetic regimen using propofol
or volatile anesthetics (46,48,128), and may interfere
with the cardioprotective effect of RIC. The interfer-
ence of propofol, which is cardioprotective per se,
with further protection by RIC contrasts with the
inherent cardioprotective effect of isoﬂurane, which
does not interfere with RIPC (46,48), suggesting a
speciﬁc interaction of propofol with neuronal transfer
of the protective RIPC signal. Although in experi-
mental studies, diabetes mellitus attenuated the ef-
fect of local ischemic pre-conditioning (130), the
degree of cardioprotection may depend on stimulus
intensity (131) and diabetes duration (132), and the
TABLE 1 Clinical Studies of RIC in Cardiac Surgery
First Author,
Year (Ref. #)
Patients, n
(Control/RIC) Type of Surgery RIC Regimen Endpoint Outcome
Günaydin et al., 2000 (93) 4/4 CABG Upper limb
2 cycles I/R (3/2 min)
CK
(Sampled via coronary
perfusion catheter 5 min
after declamping)
No effect
Cheung et al., 2006 (103) 20/17 Pediatric cardiac surgery Upper limb
4 cycles I/R (5/5 min)
TnT
(AUC 24 h after surgery)
Post-operative inotropic need
Lung function
Reduced TnT; reduced
inotropic score; reduced
airway resistance
Hausenloy et al., 2007 (104) 30/27 CABG Upper limb
3 cycles I/R (5/5 min)
TnT
(AUC 72 h after surgery)
43% reduction of TnT
Venugopal et al., 2009 (105) 22/23 CABG
(cold blood cardioplegia)
Upper limb
3 cycles I/R (5/5 min)
TnT
(AUC 72 h after surgery)
42% reduction of TnT
Hong et al., 2010 (106) 65/65 CABG
(off-pump)
Upper limb
4 cycles I/R (5/5 min)
TnI
(AUC 72 h after surgery)
26% reduction of TnT, NS
Rahman et al., 2010 (96) 82/80 CABG Upper limb
4 cycles I/R (5/5 min)
TnT
(AUC 48 h after surgery)
No effect
Thielmann et al., 2010 (107) 26/27 CABG
(crystalloid cardioplegic arrest)
Upper limb
3 cycles I/R (5/5 min)
TnI
(AUC 72 h after surgery)
45% reduction of TnI
Li, 2010 (108) 27/26 Valve replacement Lower limb
3 cycles I/R (4/4 min)
TnI
(AUC 72 h after surgery)
40% reduction of TnI
Zhou (2010) (109) 30/30 Pediatric cardiac surgery Upper limb
2 cycles I/R (5/5 min)
24 and 1 h prior to operation
CK-MB
Inﬂammatory biomarkers
(plasma levels 2, 4, 12,
and 24 h after surgery)
Lung function
Reduced CK-MB and
inﬂammatory
biomarkers
Improved post-operative
lung function
Wagner et al., 2010 (110) 34/32 CABG
(cold crystalloid cardioplegia)
Upper limb
3 cycles I/R (5/5 min)
18 h prior to operation
TnI
(AUC 24 h after surgery)
Reduced TnI
Ali et al., 2010 (111) 50/50 CABG Upper limb
3 cycles I/R (5/5 min)
CK-MB
(plasma levels 8, 16, 24,
and 48 h after surgery)
Reduced CK-MB
Karuppasamy et al., 2011 (97) 27/27 CABG Upper limb
3 cycles I/R (5/5 min)
TnI
(AUC 48 h after surgery)
No effect
Wu et al., 2011 (112) 25/25 Mitral valve replacement Upper limb
3 cycles I/R (5/5 min) and
3 cycles I/R (5/5 min)
þ 2 cycles I/R (10/10 min)
TnI
(plasma levels 4, 8, 12, 24, 48,
and 72 h after surgery)
Reduced TnI with 3 cycles
I/R (5/5 min) þ 2 cycles
I/R (10/10 min) but not
3 cycles I/R (5/5 min)
Kottenberg et al., 2012 (46) 19/20 CABG
Propofol vs. isoﬂurane
anesthesia
Upper limb
3 cycles I/R (5/5 min)
TnI
(AUC 72 h after surgery)
Reduced TnI with
isoﬂurane, but not with
propofol anesthesia
Young et al., 2012 (94) 48/48 Cardiac surgery (high-risk CABG
and valve surgery)
Upper limb
3 cycles I/R (5/5 min)
TnT
(plasma levels 6 and 12 h
surgery)
No effect
Heusch et al., 2012 (84) 12/12 CABG Upper limb
3 cycles I/R (5/5 min)
TnI
(AUC 72 h after operation)
Phosphorylation of STAT5
Reduced TnI
STAT5 activation
Lee et al., 2012 (98) 28/27 Pulmonary hypertensive infants
receiving ventricular septal
defect repair
Lower limb
4 cycles I/R (5/5 min)
TnI
AUC 24 h after surgery
No effect
Pavione et al., 2012 (99) 10/12 Pediatric cardiac surgery Lower limb
4 cycles I/R (5/5 min)
TnI
(plasma levels 4, 12, 24,
and 48 h after surgery)
No effect
Lucchinetti et al., 2012 (100) 28/27 CABG
Opioids and propofol for
induction and isoﬂurane for
maintenance anesthesia
Lower limb
4 cycles I/R (5/5 min)
TnT
(plasma levels 24, 48, and
72 h after surgery)
No effect
Xie et al., 2012 (113) 35/38 Valve surgery Upper limb
3 cycles I/R (5/5 min)
TnI
(plasma levels 6, 12, 24, 48,
and 72 h after surgery)
Reduced TnI
Thielmann et al., 2013 (114) 167/162 CABG
(cold crystalloid cardioplegia
and cardiopulmonary bypass)
Upper limb
3 cycles I/R (5/5 min)
TnI
(AUC 72 h after surgery)
27% reduction of TnI
Reduced all-cause mortality
Ahmad et al., 2014 (101) 32/35 CABG
On-pump
? CK-MB
(plasma levels 1, 12, 24,
and 48 h after surgery)
No effect
Continued on the next page
Heusch et al. J A C C V O L . 6 5 , N O . 2 , 2 0 1 5
Remote Ischemic Conditioning J A N U A R Y 2 0 , 2 0 1 5 : 1 7 7 – 9 5
184
TABLE 1 Continued
First Author,
Year (Ref. #)
Patients, n
(Control/RIC) Type of Surgery RIC Regimen Endpoint Outcome
Hong et al., 2014 (95) 636/644 Cardiac surgery
(cardiac valve surgery, CABG,
combined valve and CABG
surgery, ascending aorta and
aortic arch surgery, and
congenital heart defect repair)
Upper limb
4 cycles I/R (5/5 min)—
2 cycles before and 2 cycles
after cardiopulmonary bypass
Clinical outcome
(composite of: death,
myocardial infarction,
arrhythmia, stroke, coma,
renal damage, respiratory
failure, gastrointestinal
complications, and
multiorgan failure)
No effect
Slagsvold et al., 2014 (87) 30/30 CABG Upper limb
3 cycles I/R (5/5 min)
Mitochondrial oxidation Improved mitochondrial
respiration
McCrindle et al., 2014 (102) 151/148 Pediatric cardiac surgery Lower limb
4 cycles I/R (5/5 min)
Duration of post-operative
hospital stay
No effect
Holmberg et al., 2014 (116) 23/23 Cardiac surgery
(CABG, valve surgery, ascending
aorta, myxoma)
Upper limb
3 cycles I/R (5/5 min)
TnT
(AUC 72 h after surgery)
25% reduction of TnT, NS
Candilio et al., 2014 (115) 90/90 Cardiac surgery
(CABG and/or valve surgery)
Upper and lower limb
2 cycles I/R (5/5 min)
Perioperative myocardial
infarction
(AUC 52 h after surgery)
26% reduction of TnT
Reduction of incidence of
AF, renal failure, stay
at ICU
AF ¼ atrial ﬁbrillation; AUC ¼ area under curve; CABG ¼ coronary artery bypass grafting; CK ¼ creatine kinase; CK-MB ¼ creatine kinase-myocardial band; I ¼ ischemia; ICU ¼ intensive care unit; NS ¼ not
signiﬁcant; R ¼ reperfusion; RIC ¼ remote ischemic conditioning; STAT5 ¼ signal transducer and activator of transcription 5; Tn ¼ troponin.
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185attenuation of protection by RIC seems minor in the
clinical setting (133,134).
Importantly, recent larger studies have not only
relied on surrogate markers of cardioprotection,
but also included long-term clinical outcomes and
demonstrated a reduction of major cardiovascular
events by RIPC up to 4 years after CABG (114) and up
to 6 years after elective PCI (119). A recent study
randomized 1,280 patients scheduled for elective
cardiac surgery to control or RIPC and remote post-
conditioning (95). RIC was given as 2 cycles of 5-min
ischemia and 5 min of reperfusion on the upper arm
before cardiopulmonary bypass or coronary anasto-
moses in those who had beating heart surgery, and
was repeated in the same sequence immediately
after bypass. Although the cardioprotective effect
was not documented by a reduction of post-operative
biomarker release, RIC did not reduce the primary
endpoint, a composite of major adverse outcomes
including death, myocardial infarction, arrhythmia,
stroke, coma, renal damage, respiratory failure, gas-
trointestinal complications, and multiorgan failure,
suggesting that this endpoint may have been too
broad. Although RIC is thought to have systemic
protective effects on various distal organs, the results
are debatable because the composite endpoint dif-
fers from other studies yielding beneﬁcial results.
Moreover, the heterogeneity of the patient group,
including CABG, cardiac valve surgery, and their
combination, as well as ascending or transverse aortic
surgery and congenital heart defect repair, may have
introduced bias.Recent meta-analyses demonstrated that RIPC re-
duces biomarkers in patients undergoing CABG
(92,135). The 2 follow-up studies with clinical out-
comes were single-center trials, not powered to de-
monstrate deﬁnitive answers about clinical outcome
(114,120). The consistency of the beneﬁcial clinical
outcome in the studies adds credibility to a clinically-
relevant beneﬁt of RIC in relation to CABG and elec-
tive PCI. However, larger multicenter studies are
still required to clarify the extent to which these
ﬁndings translate into clinical beneﬁt. Future studies
should include high-risk patients, who might beneﬁt
most from protection by RIC, and preferably avoid
propofol in their anesthetic regimen when speciﬁc
cardioprotective effects are addressed.
EFFECTS OF RIC ON THE HEART: AMI. Although the
incidence of AMI is declining in the Western World
(136,137), ischemic heart disease is still the leading
cause of death worldwide (138). Improvements in
treatment have changed the epidemiology after
AMI, with markedly improved 30-day survival, but
have less favorably inﬂuenced long-term survival
(136,139). Consistent with this, due to remodeling
and heart failure (140), nonfatal ischemic heart dis-
ease has increased more than ischemic heart disease
deaths since 1990 (138). The declining incidence of
heart failure after AMI has not reached the magni-
tude that we might have expected from clinical trial
data (139) and the prevalence is increasing (138).
Consequently, one of the potentially most important
applications of RIC may be in patients with AMI
(28,141–147) (Table 3).
TABLE 2 Clinical Studies of RIC in Elective PCI
First Author,
Year (Ref. #)
Patients, n
(Control/RIC) RIC Regimen Endpoint Outcome
Iliodromitis et al., 2006 (117) 21/20 Upper limb
3 cycles I/R (3/3 min)
TnI
(12, 24, and 48 h after PCI)
No effect
Hoole et al., (118) 98/104 Upper limb
3 cycles I/R (3/3 min)
TnI
(proportion of patients with
TnI <0.04 ng/ml)
Reduction of proportion of patients
with elevated TnI
Reduced cardiac events 6 months
after PCI
Davies et al., 2013 (119) 97/95 Upper limb
3 cycles I/R (3/3 min)
MACCE at 6 years 13% reduction of MACCE
Ahmed et al., 2013 (120) 72/77 Upper limb
3 cycles I/R (3/3 min)
TnT
(Plasma level 16 h after PCI)
57% reduction of TnT
Prasad et al., 2013 (121) 48/47 Upper limb
3 cycles I/R (3/3 min)
TnT
(proportion of patients with
TnT $0.03 ng/dl)
No effect
Luo et al., 2013 (122) 104/101 Upper limb
3 cycles I/R (3/3 min)
TnI
(plasma level 16 h after PCI)
48% reduction of TnI
Xu et al., 2014 (123) 98/102 Upper limb
3 cycles I/R (3/3 min)
TnI
(plasma level 16 h after PCI)
24% reduction of TnI in DM patients
age $65 years, NS
Liu et al., 2014 (124) 102/98 Upper limb
3 cycles I/R (3/3 min)
TnI
(plasma level 24 h after PCI)
75% reduction of TnI
Reduction of adverse events at 6 months
Zografos et al., 2014 (125) 47/47 Upper limb
1 cycle I/R (5/5 min)
TnI
(increase in TnI from baseline
to 24 h after PCI)
79% reduction in post-PCI TnI increment
DM ¼ diabetes mellitus; MACCE ¼ major adverse cardiovascular and cerebral events; other abbreviations as in Table 1.
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186Most clinical studies on infarct size after coronary
revascularization have used indirect estimates of
tissue damage, such as release of biomarkers and
resolution of ST-segment elevation (148,149). Direct
visualization of the area-at-risk and ﬁnal infarct size
to calculate the salvage index (proportion of salvaged
area-at-risk) can be achieved by myocardial perfusion
imaging using 99technetium-sestamibi single-photon
emission computerized tomography (150) or cardiac
magnetic resonance (CMR) imaging (151–153). CMRTABLE 3 Clinical Studies of RIC in AMI
First Author,
Year (Ref. #)
Patients, n
(Control/RIC) RIC Regimen
Bøtker et al., 2010 (28) 69/73 Upper limb
4 cycles I/R (5/5 min)
Munk et al., 2010 (141) 110/108 Upper limb
4 cycles I/R (5/5 min)
Rentoukas et al., 2010 (142) 30/33 Upper limb
3 cycles I/R (5/5 min)
Crimi et al., 2013 (143) 50/50 Lower limb
3 cycles I/R (5/5 min)
Prunier et al., 2014 (144) 17/18 Upper limb
4 cycles I/R (5/5 min)
Sloth et al., 2014 (145) 167/166 Upper limb
4 cycles I/R (5/5 min)
Hausenloy et al., 2014 (147) 260/260 Upper limb
4 cycles I/R (5/5 min)
White et al., 2014 (146) 40/43 Upper limb
4 cycles I/R (5/5 min)
LVEF ¼ left ventricular ejection fraction; SPECT ¼ single photon emission computerizedquantiﬁcation of the area-at-risk poses challenges,
because the optimal protocol to quantify edema,
thought to represent area-at-risk, is not deﬁned
(154–156) and because any cardioprotective inter-
vention that reduces ﬁnal infarct size also may reduce
edema (157,158), potentially underestimating salvage.
The ﬁrst proof-of-concept study demonstrating
that RIC can increase myocardial salvage investigated
333 patients undergoing primary PCI for STEMI,
of whom 132 had available imaging data (28).Endpoint Outcome
Salvage index
(SPECT)
20% increase in salvage index
LVEF at 30 days 5% increase in LVEF in anterior infarcts
ST-segment resolution 20% increase in proportion of patients
achieving full ST-segment resolution
CK-MB
(AUC 72 h after PCI)
20% reduction of CK-MB release
CK-MB
(AUC 72 h after PCI)
31% reduction of CK-MB release
MACCE at 4 years 12% reduction in MACCE
TnT
(AUC 24 h after PCI)
17% reduction of TnT release
CMR 27% reduction of infarct size
tomography; other abbreviations as in Tables 1 and 2.
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187A simultaneous study demonstrated that RIC in-
creases the number of patients achieving complete
ST-segment resolution and found a statistically
borderline reduction of troponin-T release (142). In
the former study, RIC was applied as 4 cycles of 5-min
upper arm ischemia and 5-min reperfusion and was
initiated in the ambulance during transportation to
primary PCI. RIC increased salvage by 36% and ten-
ded to reduce ﬁnal infarct size. In patients with
anterior infarcts and patients with occluded culprit
artery (Thrombolysis In Myocardial Infarction [TIMI]
grade 0 to 1) on admission, infarct size reduction, as
measured by single-photon emission computed to-
mography, was 44% and 31%, respectively, indicating
that patients at highest risk beneﬁt more from RIC as
an adjunctive therapy to primary PCI. The ﬁndings
translated into an increment of left ventricular ejec-
tion fraction in anterior infarcts (141). Although not
powered to evaluate clinical outcome, a follow-up
study of the total cohort showed that the beneﬁcial
effect of RIC translated into a reduction of major
cardiovascular events up to 4 years after the index
event (145). In a recent study, 4 cycles of 5-min cuff
inﬂation/5-min deﬂation on the upper arm reduced
myocardial edema and reduced infarct size, reﬂected
by troponin release and CMR (146).
The ﬁrst window of protection lasts for 2 to 3 h and
onset appears to be instant, as RIC initiated immedi-
ately prior to revascularization also reduces infarct
size in STEMI patients (144). In some protocol algo-
rithms, remote pre-conditioning combined with local
post-conditioning reduced infarct size in rats (71).
This additive effect was not seen for remote pre-
conditioning combined with local post-conditioning
in the clinical setting of patients with reperfused
AMI (144).
In a recent randomized study of 100 patients,
remote post-conditioning also reduced infarct size, as
assessed by the area under the curve of creatine
kinase-myocardial band release (143). Infarct size was
consistently reduced, as reﬂected by delayed
gadolinium-enhancement volume on CMR and ST-
segment resolution >50% in twice as many patients
in the treatment than in the control group. After
1-year follow-up, 1 patient in the control group
(refractory heart failure) and none in the post-
conditioning group had died, and cardiovascular
events were reduced in the treatment group. The
beneﬁcial effect was obtained by 3 cycles of 5-min/
5-min blood pressure cuff inﬂation/deﬂation of the
lower limb initiated at the time of reperfusion by
balloon inﬂation or thrombectomy. Although a recent
clinical study suggested that 1 occlusion cycle induces
protection during elective PCI (125), experimentaldata from mice indicate that cardioprotective efﬁcacy
is determined by the number and duration of in-
ﬂations (34).
Present reperfusion therapy is effective in the
majority of patients undergoing primary PCI. It may
be difﬁcult to demonstrate additional clinical beneﬁt
from further intervention because this would require
the demonstration of further reduction in small
myocardial infarcts and its translation into a clinical
beneﬁt. A subgroup of patients undergoing not only
primary PCI, but also elective PCI and CABG, develops
serious complications, including extensive myocar-
dial injury, which is most frequently vascular in
origin. Although pre-clinical human data indicate that
RIC may modify thrombogenesis (159,160) and yield
cardioprotection beyond an unequivocal reduction of
infarct size (e.g. by anti-inﬂammatory mechanisms)
(161), the clinical implications are yet unknown.
However, some patients, predominantly those with
large anterior infarcts, develop heart failure due to
myocardial injury and subsequent left ventricular
remodeling several months or years after the infarct,
despite optimal medical treatment according to
guidelines (140). Because RIC reduces ﬁnal tissue
necrosis, improved clinical outcome must be assessed
by reduced post-infarction left ventricular dys-
function and heart failure, combined with mortality
reduction (162). To achieve widespread clinical
acceptance of RIC, focus should be kept on patients
at risk of extensive myocardial injury and global
tissue damage. Its potential clinical utility is far from
fully explored.
An emerging concept, known as chronic condi-
tioning, is the daily use of RIC for a period of weeks.
In rats, RIC administration daily for the ﬁrst 28 days
after myocardial infarction had a dose-dependent
effect on cardiac remodeling, heart failure, and even
death rate in the absence of a signiﬁcant reduction of
infarct size (163). This effect demonstrates beneﬁts
beyond modiﬁcation of acute ischemic effects. How-
ever, in a recent pilot study, this did not immediately
translate into improved exercise capacity in heart
failure patients (50).
CONFOUNDING FACTORS IN RIC
No recognized effective therapeutic intervention for
protecting the myocardium against the detrimental
effects of ischemia-reperfusion injury presently ex-
ists. A major reason for this unfortunate situation is
the inability to take the relevance of confounding
factors present in the majority of basic and clinical
studies into account; RIC studies are no different in
this regard (126).
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188INFARCT LOCATION/PATIENT SELECTION. Only a
quarter of all STEMI patients have infarcts of sufﬁ-
cient size to beneﬁt from adjunctive therapy (164).
Patients presenting with right and/or circumﬂex cor-
onary artery occlusion, where the infarct is relatively
small, do not beneﬁt as much from cardioprotective
therapy as those presenting with proximal left ante-
rior descending coronary artery occlusion, where
the infarct is signiﬁcantly larger (28,165). “All-comer”
trials will lead to the recruitment of far more patients
with small infarcts and little additional myocardial
salvage, which may actually dilute the positive effect
elicited by any novel protective strategy. Alterna-
tively, limiting recruitment to patients with large
anterior infarcts is more challenging because they
are the most ill (166); however, the beneﬁt of proof-
of-concept trials is that demonstration of a signi-
ﬁcant difference between treatment and placebo
requires recruitment of fewer patients (167).
CONTROL OF TIMI FLOW PRIOR TO RIC. Some pa-
tients presenting with an AMI have already under-
gone spontaneous reperfusion prior to interventional
reperfusion and are not likely to beneﬁt from a ther-
apy designed to protect against reperfusion injury
(168). Therefore, only those patients with TIMI
scores <1 should be included in such studies (28).
IMPORTANCE OF CORONARY COLLATERALS. The
coronary collateral circulation’s ability to inﬂuence
the size of an evolving myocardial infarction cannot
be underestimated. In STEMI patients, substantial
collateralization reduces the sizes of the area at
risk and the evolving infarct. The extent of collater-
alization will thus negatively inﬂuence the ability to
demonstrate an effect of any novel cardioprotective
strategy. Patients with visible collaterals (Rentrop
grade $1) should, therefore, be excluded (169).
DURATION OF CHEST PAIN AND TIMING OF INTER-
VENTION. Patients presenting with an AMI who
receive interventional or thrombolytic reperfusion
must do so within 12 h of the onset of chest pain
(170,171). Given the crucial events that occur in the ﬁrst
few minutes of reperfusion (oxidative stress, calcium
overload, and mitochondrial permeability transition
pore opening), any cardioprotective strategy must be
applied prior to opening the infarct-related coronary
artery. Accordingly, RIC given to patients in the
ambulance while in transit to the interventional center
have demonstrated a beneﬁcial effect (28).
With late presentation, the infarct will have been
completed, and the patient will derive little beneﬁt
from either intervention or an adjunct to reperfu-
sion. Early presentation and revascularization will
lead to small myocardial infarcts, and this patientwill have little advantage from adjunctive therapy.
There is a “sweet spot,” probably between 3 and 8 h
from time of symptom onset to time of reperfusion,
for adjunctive therapies to demonstrate maximal
beneﬁt.
COMORBIDITIES AND COMEDICATIONS. In pre-
clinical studies, age (172) and comorbid diseases
(126), such as hyperlipidemia, diabetes, and hyper-
tension, which require a more robust conditioning
signal, raise the threshold for protection. This
raised cardioprotective threshold reﬂects funda-
mental molecular alterations within the heart,
affecting both sensitivity to ischemia/reperfusion
injury and response to a particular cardioprotective
strategy (126,172–174). Unfortunately, most experi-
mental models use healthy young animals, free of any
comorbidities (175). Experimental studies using hu-
man atrial muscle from patients undergoing CABG,
from aged and diabetic patients and patients with
heart failure (176–178) conﬁrmed the effect of comor-
bidity on the conditioning threshold and demon-
strated resistance to various conditioning strategies.
Pharmacological therapy also impacts cardio-
protection. Speciﬁc sulfonylureas used to treat type
2 diabetes can attenuate the conditioning response
(134). Conversely, insulin, metformin, some statins,
angiotensin-converting enzyme inhibitors, antiplate-
let agents, and opioids can themselves be cardio-
protective and raise the threshold for an additional
beneﬁt (64,173,179–181). A number of pharmacological
agents used during cardiopulmonary bypass surgery
interfere with the cardioprotective efﬁcacy of RIC.
Volatile anesthetics, such as isoﬂurane, and the intra-
venous anesthetic, propofol, either themselves confer
cardioprotection or interfere with RIC through down-
regulation of cardioprotective signaling (46,48). In-
travenous nitroglycerine, nitroprusside, and opioid
analgesics, each protective in experimental settings,
also interfere with the apparent cardioprotective
efﬁcacy of a study intervention (173,180).
Taking these confounders into consideration in
the design of any clinical study investigating RIC is
hugely important; we must either design a study that
does not use these agents (which may be impractical)
or ensure that it is adequately powered and properly
randomized.
EFFECTS OF RIC ON THE BLOOD
AND VASCULATURE
Platelet activation is both a consequence and a driver
of ischemia/reperfusion injury. Local ischemic pre-
conditioning attenuates platelet activation and ag-
gregation (182). In humans, marked systemic platelet
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189activation has been demonstrated in patients
with acute coronary syndromes (183) or acute limb
ischemia (184). In animal models, the extent of
platelet activation is related to the extent of subse-
quent tissue injury after reperfusion (185). Indeed,
blockade of platelet aggregation alone can signiﬁ-
cantly attenuate reperfusion injury. In healthy male
volunteers subjected to 20-min forearm ischemia
(160), platelet activation (measured by increased
circulating monocyte-platelet aggregates) persisted
up to 45 min, but was completely abolished in sub-
jects randomized to receive RIPC prior to the ischemic
insult. In patients with known obstructive coronary
artery disease (186), RIPC prior to exercise stress
testing reduced ADP-stimulated platelet aggregation.
Similarly attenuated platelet aggregation was seen in
patients undergoing ablation for atrial ﬁbrillation
when receiving RIPC (187). However, the potential
clinical beneﬁt of any of these ﬁndings remains to be
seen.
Circulating monocytes play a key role in ischemia/
reperfusion injury. RIC down-regulated the expression
of a broad portfolio of proinﬂammatory genes in
circulating monocytes (161). The functional impor-
tance of these gene expression changes was
demonstrated by reduced neutrophil adhesion over
10 days of daily RIC (188). Neutrophil phagocytosis
was not signiﬁcantly altered at 24 h, but was sup-
pressed after 10 days of RIC. In patients undergoing
CABG (189), RIC was not associated with any dif-
ference in circulating markers of inﬂammation (e.g.,
interleukins 6, 8, or 10, or tumor necrosis factor-a
levels) but neutrophil kinase beta-1 and beta-2
receptor expression was signiﬁcantly reduced, con-
ﬁrming similar results in healthy human volunteers
subjected to RIC (190).
The RIC stimulus is associated with coronary
vasodilation in animal models (191) and peripheral
vasodilation in the contralateral limb of human sub-
jects undergoing RIC (192). In Kharbanda’s original
description (17), RIPC by 3 cycles of 5-min ischemia/
5-min reperfusion in the forearm provided potent
protection against the endothelial dysfunction
induced by 20-min ischemia/reperfusion in the
contralateral arm. Using the samemodel, RIPC was not
only effective immediately, but also induced a second
window of protection against endothelial dysfunction
at 24 h (44). When the RIC protocol was performed on
the contralateral arm during the ischemia phase, but
prior to reperfusion, both RIPC and remote ischemic
per-conditioning were blocked by pre-treatment with
the ATP-dependent potassium channel blocker, gli-
benclamide (193). Compared with young volunteers,
elderly hypertensive subjects beneﬁtted more fromRIC, whereas basal levels of ﬂow-mediated dilation
were signiﬁcantly greater in the younger population
(194). RIC in healthy young subjects, repeated daily for
7 days (195), was associated with progressively
improved ﬂow-mediated dilation and cutaneous
vascular conductance (as a measure of microcircula-
tory function), which was sustained at 8 days after the
cessation of RIC. In a subsequent study (196), similar
beneﬁcial effects persisted after 8 weeks of repeated
RIC treatments. This prolonged effect of RIC on
endothelial function was also observed in patients
with AMI undergoing PCI (197). Endothelial function
was tested at baseline, within 3 h, and then on days 2
and 7 post-procedure in 48 patients randomized to
PCI with or without RIPC. Endothelial function
improved early after treatment and was sustained
7 days after the intervention. Whether this was a pri-
mary effect of sustained modiﬁcation of endothelial
function or a secondary phenomenon, resulting from
less systemic inﬂammatory reaction, is unknown.
Likewise, 1 week of twice-daily limb RIC improved
ATP-recruitable coronary blood ﬂow velocity reserve
in a small cohort of healthy volunteers and patients
with heart failure (198).
CONCLUSIONS AND PERSPECTIVE
Solid evidence from experimental and clinical studies
supports protection by RIC from ischemia/reperfu-
sion injury of the heart and other organs (16). Details
of the mechanisms for local release of the protective
signal at the remote site and the contributions of
neuronal and humoral pathways are not yet clear,
not only in signal release, but also in signal transfer
to the target organ and protective signal transduction
within the target organ. Repeated brief inﬂation/
deﬂation of a blood pressure cuff at the arm, leg, or
both is easily feasible, noninvasive, inexpensive,
effective, and safe. Ongoing trials will reveal whether
the beneﬁt in clinical outcome reported from small
proof-of-concept trials where clinical outcome was
not the primary endpoint (199) will really hold true
(200,201).
Thus far, translation of cardioprotective strategies
from successful experiments to the clinic has been
somewhat disappointing, for reasons that have been
highlighted elsewhere (64,166,167,202): premature
enthusiasm for experimental data that were not un-
equivocal and not conﬁrmed in larger mammalian
models; poor clinical trial design; and lack of con-
sideration for patients’ multiple comorbidities and
comedications (126). The pharmaceutical industry
has, understandably, largely given up on develop-
ment of cardioprotective agents, because they may
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190need to be given only once in the situation of acute
ischemia/reperfusion, but not as continuous therapy.
It appears reasonable to focus on mechanical pro-
tection of the heart and other organs by RIC and to
optimize protocols. Apart from RIC algorithm opti-
mization (number/duration of ischemia/reperfusion
cycles), a better mechanistic understanding of the
underlying signal transduction will be necessary to
overcome the confounding impact of comorbidities
and comedications. RIC may then, indeed, be the
future of cardioprotection (203).
Future investigations should explore the potential
beneﬁt of RIC, not only in patients with largeevolving myocardial infarctions, but also in patients
with cardiogenic shock and severe arrhythmias,
including cardiac arrest and threatening global
ischemia of the brain, heart, liver and kidney during
organ transplantation and extensive cardiovascular
surgery.
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